Hancock Bruno C, Carlson Glenn T, Ladipo Dauda D, Langdon Beth A, Mullarney Matthew P
Pfizer Inc., MS 8156-006, Eastern Point Road, Groton, CT 06340, USA.
Int J Pharm. 2002 Jul 8;241(1):73-85. doi: 10.1016/s0378-5173(02)00133-3.
To better understand the influence of long-range molecular order on the processing characteristics of an active pharmaceutical ingredient (API).
Crystalline and amorphous samples of a model drug substance were isolated and their "true" density, crystallinity, melting point, glass transition temperature, particle size distribution, and powder flow characteristics determined. Compacts of a standard porosity were manufactured from each form and their dynamic indentation hardness, quasi-static indentation hardness, tensile strength and "compromised tensile strength" determined. X-ray powder diffraction was used to confirm that no changes were induced by compact formation or testing.
The crystalline and amorphous forms of the drug substance had relatively high melting and glass transition temperatures (approximately 271 and 142 degrees C, respectively) and were physically and chemically stable under the conditions of the testing laboratory. Consistent with this there was no evidence of crystallinity in the amorphous samples or vice versa before, during or after testing. The two API lots were effectively equivalent in their particulate properties (e.g. particle size distribution), although differences in their particle morphologies were observed which influenced powder flow behavior. The compacts of the bulk drug samples exhibited moderate ductility, elasticity, and strength, and high brittleness, in keeping with many other drug substance samples. A significantly greater compression stress was required to form the compacts of the crystalline material, and these sample materials were more ductile, less brittle and less elastic than those made from the amorphous API. There were no major differences in the tensile strength or the viscoelasticity of the compacts made from the crystalline and amorphous samples.
The mechanical properties of compacted amorphous and crystalline samples of a drug substance have been measured and the contributions due to the molecular ordering of the crystalline form proposed. Small but significant differences in the mechanical properties were noted which could potentially affect the processing performance of API.
为了更好地理解长程分子有序性对活性药物成分(API)加工特性的影响。
分离出一种模型药物的结晶态和非晶态样品,并测定其“真实”密度、结晶度、熔点、玻璃化转变温度、粒度分布和粉末流动特性。由每种形态制备标准孔隙率的压片,并测定其动态压痕硬度、准静态压痕硬度、拉伸强度和“折减拉伸强度”。采用X射线粉末衍射法确认压片形成或测试过程中未引起变化。
该药物的结晶态和非晶态具有相对较高的熔点和玻璃化转变温度(分别约为271℃和142℃),且在测试实验室条件下物理和化学性质稳定。与此一致的是,在测试前、测试期间或测试后,非晶态样品中均无结晶迹象,反之亦然。尽管观察到两种API批次在颗粒形态上存在差异,影响了粉末流动行为,但它们在颗粒性质(如粒度分布)方面实际上是等效的。原料药样品的压片表现出适度的延展性、弹性和强度,以及较高的脆性,这与许多其他原料药样品一致。形成结晶材料的压片需要显著更大的压缩应力,并且这些样品材料比由非晶态API制成的材料更具延展性、更不易脆且弹性更小。由结晶态和非晶态样品制成的压片在拉伸强度或粘弹性方面没有重大差异。
已测量了药物压实的非晶态和结晶态样品的机械性能,并提出了结晶态分子有序性所起的作用。注意到机械性能存在微小但显著的差异,这可能会潜在地影响API的加工性能。